MedTrace Logo

The Implementation of the Automated Erythrocytapheresis in Egyptian Sickle Cell Disease Center

NCT03903289 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2024-01-11

No results posted yet for this study

Summary

Improvements of health infrastructure, preventive care and clinical treatment have reduced the morbidity and mortality of sickle cell disease (SCD). However, SCD is still an increasing national health problem, with increase longevity the chronic effect of sustained hemolysis and episodic vaso-occlusive events and the recurrent episodes of ischemic reperfusion injury drive the development of progressive end organ complications and cardiovascular, pulmonary, neurological and renal systems are most commonly affected. Today there is hope for a cure using hematopoietic stem cell transplantation (HSCT). However, at present; the procedure is infrequently performed and very expensive. In this research we will assess the effect of implementation of the automated erythrocytapheresis in the outcome of sickle cell disease in single Egyptian center.

Conditions

Interventions

PROCEDURE

Automated red cell exchange

Erythrocytapheresis is an automated red cell exchange procedure that removes blood that contains HbS from the patient while simultaneously replacing that same volume with packed red cells free of HbS.

PROCEDURE

Manual red cell exchange

Active Comparator: Manual red cell exchange

PROCEDURE

Simple red cell transfusion

Active Comparator: Simple red cell transfusion

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Principal Investigators

  • Fatma Solima SE Ebeid, MD · Faculty of Medicine, Ain Shams university

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
2 Years
Max Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-16
Primary Completion
2025-12-31
Completion
2026-01-31

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03903289 on ClinicalTrials.gov